ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

Sun, 12 Apr 2026 02:40:07 +0000
Intellectual Property

The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.